GRCE - Grace Therapeutics, Inc.
Grace Therapeutics, Inc. Logo

GRCE - Grace Therapeutics, Inc.

https://www.gracetx.com
Momentum: Bearish
Recent News
Powered by Alpha Vantage

No recent news found.

AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company is headquartered in Princeton, New Jersey.

52W High
$4.97
52W Low
$1.75

MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
1.37
Valuation
As of 2024-09-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
N/A
EV/Revenue (<3 favorable)
N/A
P/S (TTM) (<3 favorable)
N/A
P/B (<3 favorable)
0.62
Ownership
Retail‑heavy
Source: Overview
Insiders (1–5% typical)
38.39%
Institutions (25–75% balanced)
20.59%
Shares Outstanding
10,139,900
Float
4,952,300
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2024-09-30 (Overview)
Revenue (TTM)
0
Gross Profit (TTM)
0
EPS (TTM)
-1.29
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-0.23%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Bearish momentum
Value
0.0220
Previous
0.0273
Trend
Falling
Signal Cross
No cross

As of
Sep. 12, 2025